Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler
about
In Vitro Testing for Orally Inhaled Products: Developments in Science-Based Regulatory ApproachesEvaluation of Aerosol Delivery of Nanosuspension for Pre-clinical Pulmonary Drug DeliveryInhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study.In vitro and in vivo performance of dry powder inhalation formulations: comparison of particles prepared by thin film freezing and micronization.Effect of delivery device on systemic exposure to inhaled fluticasone propionate in children with asthma.A new methodology for predicting human pharmacokinetics for inhaled drugs from oratracheal pharmacokinetic data in rats.Treatment of eosinophilic esophagitis: is oral viscous budesonide superior to swallowed fluticasone spray?Incident pneumonia and mortality in patients with chronic obstructive pulmonary disease. A double effect of inhaled corticosteroids?Budesonide/formoterol for the treatment of asthma.Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective.Plasma concentrations of inhaled corticosteroids in relation to airflow obstruction in asthma.Fluticasone propionate/salmeterol for the treatment of chronic-obstructive pulmonary disease.An integrated model for the effect of budesonide on ACTH and cortisol in healthy volunteers.Self-reported osteoporosis prevention in inhaled corticosteroid users in community pharmacy settingTherapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthmaAirway selectivity: an update of pharmacokinetic factors affecting local and systemic disposition of inhaled steroids.Evidence-based selection of inhaled corticosteroid for treatment of chronic asthma.Evidence of the in vivo esterification of budesonide in human airways.Long-Term Fluticasone Propionate/Formoterol Fumarate Combination Therapy Is Associated with a Low Incidence of Severe Asthma Exacerbations.Inhaled corticosteroids in COPD and the risk of serious pneumonia.Differences in the pharmacodynamics of budesonide/formoterol and salmeterol/fluticasone reflect differences in their therapeutic usefulness in asthma.Comparison of inhaled corticosteroids: an update.The association between inhaled corticosteroid and pneumonia in COPD patients: the improvement of patients' life quality with COPD in Taiwan (IMPACT) study.The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial.Advances in the pulmonary delivery of poorly water-soluble drugs: influence of solubilization on pharmacokinetic properties.Between-Batch Pharmacokinetic Variability Inflates Type I Error Rate in Conventional Bioequivalence Trials: A Randomized Advair Diskus Clinical Trial.What is the potential for inhaled p38 inhibitors in the treatment of chronic obstructive pulmonary disease?Neonatal pharmacology: extensive interindividual variability despite limited size.The PulmoSphere™ platform for pulmonary drug delivery.Integration of active pharmaceutical ingredient solid form selection and particle engineering into drug product design.Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist.Evaluating the suitability of using rat models for preclinical efficacy and side effects with inhaled corticosteroids nanosuspension formulations.A pharmacokinetic simulation tool for inhaled corticosteroids.Lung deposition and systemic availability of fluticasone Diskus and budesonide Turbuhaler in children.Predicting Pulmonary Pharmacokinetics from In Vitro Properties of Dry Powder Inhalers.Aerosol particle size does not predict pharmacokinetic determined lung dose in children.Pharmacokinetics of budesonide and formoterol administered via a series of single-drug and combination inhalers: four open-label, randomized, crossover studies in healthy adults.Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD.A compartment-quasi-3D multiscale approach for drug absorption, transport, and retention in the human lungs.New techniques for studying airway drug pharmacokinetics for asthma therapeutics.
P2860
Q28080832-52E2FCAA-CAF3-4262-A890-0E041EDDEDB1Q28396497-96CDD7EC-D0C5-4779-B8F8-C040DBA65768Q33705358-D35F7041-8AE7-4172-863C-A4EC3C292D00Q33962560-B408E945-64DE-4A30-BD89-8DFA32EB7FE0Q34065347-05604839-369A-42FA-B411-E3F199A9B2C6Q34072885-8A0B8738-119A-4C20-B5E9-55BC08A753C1Q34571174-8A202EA8-7C61-4CC2-B14C-1C11479A3833Q35140742-EC84B32E-1B30-43FE-BCAA-8B706FA114CBQ35183771-C6024073-B66C-4DA1-BC6A-937A9CB5333FQ35610011-75426C81-CEDE-472F-B8C0-6A280F67B28EQ35827816-C055681E-EA75-4CD2-99E2-BD48C167818BQ35841604-7F997964-C50E-48EB-890F-063AD4D2FDCBQ36024571-935EDBE8-5161-4C3B-BB80-95800F9AF397Q36372071-3B3225C0-6B9B-4049-AE52-ECE2680D6ED2Q36432119-1A4E0968-BA29-4679-9987-3DF0E2B996D8Q36478796-BFF3B0B6-6B18-4888-8C06-AC5D3021F269Q36761823-CD440DDF-811B-488D-9B5A-6E522A092101Q36792765-66E45D82-40B4-4253-B102-B4AF24EC99DBQ37137128-58BF8573-95AA-4679-9284-F401A11ABF37Q37267655-3645EB8B-0E8D-4B6B-ABCE-7F41CA50EF0EQ37362634-57819D42-D785-4C8D-8BBB-56EE910FD55EQ37406595-32E69A5E-C61F-426B-BF88-ACBA54567013Q37412962-4CF37608-E751-43EC-AB11-A94D641974BCQ37428235-176E8F3F-8C2C-4A78-BF17-E8F26477642EQ37565681-C2B6596F-A373-48A4-8B26-FE5778CCC404Q37664466-1890F056-1B3B-4E31-BB66-E06A79DB5551Q37937555-515C826B-2532-4B8E-91E1-3609FA614589Q38000252-F1A72220-8761-4D24-BA11-EAC23FE65415Q38193170-51FFA10B-6B7D-4776-9E52-F37996E48D89Q38353795-5653C730-7A06-46AB-B267-B486B53DD356Q41522629-CCDBC917-95C2-45A1-B340-7C34571574DAQ41543788-8E52D2D1-EDE4-4002-8C63-6BE2434AB3B7Q42507245-931254CB-4CE7-4CBC-AF61-80C6EE81CB7FQ44534203-8B5B4047-9A3B-4561-9BD7-5741FFF2B448Q45065170-3EF9B010-45D9-4BC8-8672-D20A1700F7B1Q46196254-9F796B00-B4BD-4F48-A9C3-79D8D7E362A9Q46486322-4EA5E969-8AE1-4561-B3E2-806DC42C6148Q47096485-A72B0C61-BC48-4FF5-A340-956AC88DE3ECQ48355199-F4945B13-AA8C-4678-9CCA-F33A1FA74211Q51088475-34806AD0-8E97-4F3F-8961-97F78533DA3B
P2860
Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Pharmacokinetics and systemic ...... d of budesonide via Turbuhaler
@ast
Pharmacokinetics and systemic ...... d of budesonide via Turbuhaler
@en
Pharmacokinetics and systemic ...... d of budesonide via Turbuhaler
@nl
type
label
Pharmacokinetics and systemic ...... d of budesonide via Turbuhaler
@ast
Pharmacokinetics and systemic ...... d of budesonide via Turbuhaler
@en
Pharmacokinetics and systemic ...... d of budesonide via Turbuhaler
@nl
prefLabel
Pharmacokinetics and systemic ...... d of budesonide via Turbuhaler
@ast
Pharmacokinetics and systemic ...... d of budesonide via Turbuhaler
@en
Pharmacokinetics and systemic ...... d of budesonide via Turbuhaler
@nl
P2093
P2860
P3181
P1476
Pharmacokinetics and systemic ...... d of budesonide via Turbuhaler
@en
P2093
C G Löfdahl
L Thorsson
S Edsbäcker
P2860
P304
P3181
P356
10.1046/J.0306-5251.2001.01493.X
P407
P577
2001-11-01T00:00:00Z